| 
						 
						
							
								
									CIRSE  | September 14th - 18th  | Lisbon, Portugal  | Booth #69
									
									JOIN OUR SYMPOSIA 
								 
									 
							 | 
						 
						
							
								
									
										
											 
										 | 
										
											
										 | 
										
											 
												c-TACE combined with immunotherapy 
												in unresectable HCC: at the dawn of a 
												new era!
											 
										 | 
									 
								 
							 | 
						 
						
							
								
									
										
											| 
												
											 | 
											
												
													
														
															
																
																	
																		
																			
																				Harnessing synergy: evidence and future prospects in combining  c-TACE with immunotherapy
																			 
																			Dr. Lynn Savic - 
																			Charité Berlin, University Medicine. Berlin, Germany.
																		 
																	 | 
																 
															 
														 | 
													 
													
														
															
																
																	
																		
																			
																				Molecular signatures and immunogenicity of conventional TACE in  patients with HCC
																			 
																			Dr. Rafael Duran - 
																			Lausanne University Hospital. Lausanne, Switzerland.
																		 
																	 | 
																 
															 
														 | 
													 
													
														
															
																
																	
																		
																			
																				How immunotherapy associated with c-TACE might impact the treatment of HCC?
																			 
																			Moderator:
																			Dr. Julius Chapiro - 
																			Yale School of Medicine. Yale, USA.
																		 
																	 | 
																 
															 
														 | 
													 
													
														| 
															
														 | 
													 
													
														| 
															
														 | 
													 
												 
											 | 
										 
									
								 
							 | 
						 
						
							
								
									
										
											 
										 | 
										
											
										 | 
										
											 
												cTACE vs. Y90 in HCC 
												Revolution or Co-evolution?
											 
										 | 
									 
								 
							 | 
						 
						
							
								
									
										
											| 
												
											 | 
											
												
													
														
															
																
																	| 
																		 
																			Moderator:
																			Dr. Michael C. Soulen 
																			University of Pennsylvania Abramson Cancer Center. Pennsylvania, USA.
																		 
																	 | 
																 
															 
														 | 
													 
													
														
															
																
																	
																		
																			
																				c-TACE advocate
																			 
																			Dr. Maxime Ronnot - 
																			AP-HP Hôpital Beaujon. Clichy, France
																		 
																	 | 
																 
															 
														 | 
													 
													
														
															
																
																	
																		
																			
																				Y90 defender
																			 
																			Irene Bargellini  - 
																			University of Pisa, Pisa, Italy.
																		 
																	 | 
																 
															 
														 | 
													 
													
														| 
															
														 | 
													 
												 
											 | 
										 
									
								 
							 | 
						 
						
							
								
									
										
											| 
												 MEET THE EXPERTS 
											 | 
										 
										
											
												
													
														
															
																
																	
																		
																			
																				
																					
																						
																							
																								
																									
																										
																											
																												
																													
																														
																															 
																														 | 
																														
																															Saturday, Sept 14th 
																															15:00 - 16:00 (WEST)
																														 | 
																													 
																													
																														 | 
																														
																															Immunologic effects of minimally 
																															invasive tumor therapies – the 
																															ImmuMITT study
																														 | 
																													 
																												
																											 
																										 | 
																									 
																									
																										
																											
																												
																													
																														
																															 
																														 | 
																														
																															Dr. Lynn Savic 
																															
																																Charité Berlin, University Medicine.
																																Berlin, Germany.
																															 
																														 | 
																													 
																												
																											 
																										 | 
																									 
																								
																							 
																						 | 
																					 
																				
																			 
																		 | 
																	 
																	
																		| 
																			
																		 | 
																	 
																 
															 | 
															
																
															 | 
														 
													
												 
											 | 
										 
										
											
												 
											 | 
										 
									
								 
							 | 
						 
						
							
								
									
										
											
												
													
														
															| 
																 IMMERSE YOURSELF IN THE CATH-LAB 
															 | 
														 
														
															| 
																 
																	Watch every detail of how experts use Lipiodol® in their practice. All the gain with none of the strain! 
																	Every day from 09:30 to 17:00 (WEST) depending on availability
																 
															 | 
														 
													
												 
											 | 
										 
										
											
												 
											 | 
										 
									
								 
							 | 
						 
						
						
							
								
									
										
											
												
													
														
															
																
																	
																		
																			 
																		 | 
																	 
																	
																		| 
																			 
																				For the SmPC, please ask a representative on the booth.
																				This information is intended for an international audience or is provided during
																				an international event. Lipiodol® Ultra Fluid (Ethyl esters of iodized fatty acids
																				of poppy seed oil) is not registered in all countries. Be aware that Indications,
																				posology, and presentations may differ from country to country. For current
																				and complete prescribing information refer to the local Summary of Product
																				Characteristics (SmPC) and /or contact your local Guerbet organization.
  
																				RCM local disponível no stand.
																				Esta informação destina-se a um público internacional ou é fornecida durante um
																				evento internacional. O Lipiodol® Ultra Fluído (ésteres etílicos de ácidos gordos
																				iodados de óleo de sementes de papoila) não está registado em todos os países
																				pelo que a sua posologia e as apresentações podem diferir de país para país.
																				Para mais informações por favor consultar o RCM local e/ou o titular de AIM.
																			 
																		 | 
																	 
																	
																		| 
																			
																				Legal mentions & SmPC
																			
																		 | 
																	 
																 
															 | 
															
																
																	
																		
																			 
																		 | 
																	 
																	
																		| 
																			 
																				For the SmPC, please ask a representative on the booth.
																				For more information, please refer to your local product information. Elucirem™
																				(Gadopiclenol) is not registered in all countries. In countries where Elucirem™
																				(Gadopiclenol) is registered, be aware that Indications and presentations may
																				differ from country to country. For complete information please refer to your
																				local SmPC.
  
																				RCM local disponível no stand
																				O Elucirem™ (Gadopiclenol) não está registado em todos os países pelo
																				que as suas indicações e as apresentações podem diferir de país para país.
																				Para mais informações por favor consultar o RCM local e/ou o titular de AIM.
																			 
																		 | 
																	 
																	
																		| 
																			
																				Legal mentions & SmPC
																			
																		 | 
																	 
																 
															 | 
														 
													
												 
											 | 
										 
									
								 
							 | 
						 
						
							| 
								 
									© Guerbet Group 2024
								 
							 | 
						 
						
							
						 
						
							| 
								 P24002985 – August 2024 
							 | 
						 
					 
				 |